Post Marketing Observational Study to Assess Quality of Life Changes in Swedish Patients With Moderate or Severe Hidradenitis Suppurativa (HS) After 6 Months on Adalimumab Treatment (HOPE Study)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms HOPE
- Sponsors AbbVie
- 06 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 05 May 2017 Planned End Date changed from 1 Sep 2017 to 31 Mar 2018.
- 05 May 2017 Planned primary completion date changed from 1 Sep 2017 to 31 Mar 2018.